CAS 1009298-59-2

AZD-2014

Description:

AZD-2014, also known as a selective inhibitor of the mTOR (mechanistic target of rapamycin) pathway, is a compound that has garnered attention in the field of cancer research. It is classified as a small molecule and is primarily investigated for its potential therapeutic applications in various malignancies, particularly those with dysregulated mTOR signaling. The substance exhibits characteristics typical of mTOR inhibitors, including the ability to impede cell proliferation and induce apoptosis in cancer cells. AZD-2014 has shown promise in preclinical studies, demonstrating efficacy in inhibiting tumor growth and enhancing the effects of other anticancer agents. Its mechanism of action involves the disruption of the mTOR signaling cascade, which plays a crucial role in cell growth, metabolism, and survival. Additionally, AZD-2014 is characterized by its pharmacokinetic properties, which influence its absorption, distribution, metabolism, and excretion in biological systems. Ongoing research aims to further elucidate its therapeutic potential and optimize its use in clinical settings.

Formula: C25H30N6O3

InChI: InChI=1S/C25H30N6O3/c1-16-14-33-11-9-30(16)23-20-7-8-21(18-5-4-6-19(13-18)24(32)26-3)27-22(20)28-25(29-23)31-10-12-34-15-17(31)2/h4-8,13,16-17H,9-12,14-15H2,1-3H3,(H,26,32)/t16-,17-/m0/s1

InChI key: JUSFANSTBFGBAF-IRXDYDNUSA-N

SMILES: C[C@H]1COCCN1C2=NC(=NC3=C2C=CC(=N3)C4=CC(=CC=C4)C(=O)NC)N5CCOC[C@@H]5C

Benzamide, 3-[2,4-bis[(3S)-3-methyl-4-morpholinyl]pyrido[2,3-d]pyrimidin-7-yl]-N-methyl-

CAS: 1009298-59-2

Formula: C₂₅H₃₀N₆O₃

Purity: 95%

Color and Shape: Solid

Molecular weight: 462.5441

Ref: IN-DA000382

Vistusertib

CAS: 1009298-59-2

Vistusertib

Formula: C₂₅H₃₀N₆O₃

Purity: 99%

Molecular weight: 462.54

Ref: 54-BUP05651

AZD2014

Controlled Product

CAS: 1009298-59-2

Applications AZD2014 is a dual mTORC1 and mTORC2 inhibitor. Studies show that AZD2014 induces growth inhibition and cell death in breast cancer cell lines, including ER+ cell lines.
References Guichard, S.M. et al.: Cancer Res., 71, 917 (2012);

Formula: C₂₅H₃₀N₆O₃

Color and Shape: Neat

Molecular weight: 462.54

Ref: TR-A808115

Vistusertib

CAS: 1009298-59-2

Vistusertib (AZD2014) is an orally bioavailable inhibitor of the mammalian target of rapamycin (mTOR) with potential antineoplastic activity.

Formula: C₂₅H₃₀N₆O₃

Purity: 97.08% - 99.06%

Color and Shape: Solid

Molecular weight: 462.5441

Ref: TM-T1961

3-(2,4-Bis((S)-3-methylmorpholino)pyrido[2,3-d]pyrimidin-7-yl)-N-methylbenzamide

CAS: 1009298-59-2

3-(2,4-Bis((S)-3-methylmorpholino)pyrido[2,3-d]pyrimidin-7-yl)-N-methylbenzamide

Formula: C₂₅H₃₀N₆O₃

Purity: 98%

Molecular weight: 462.54

Ref: IN-DG291524

AZD-2014

CAS: 1009298-59-2

Ref: 7W-GW5430

Osimertinib Impurity 1 (AZD2014)

CAS: 1009298-59-2

Formula: C₂₅H₃₀N₆O₃

Molecular weight: 462.56

Ref: 4Z-A-194011

Vistusertib

CAS: 1009298-59-2

Formula: C₂₅H₃₀N₆O₃

Molecular weight: 462.5

Ref: BE-RMCA353011

Vistusertib

CAS: 1009298-59-2

Purity: 98%

Molecular weight: 462.5539856

Ref: 10-F787558

Vistusertib

CAS: 1009298-59-2

Vistusertib is a potent and selective inhibitor of the mammalian target of rapamycin complex 1 (mTORC1) that inhibits the activation of Akt, a downstream protein kinase. mTORC1 is an important regulator of cell growth, survival, proliferation, and metabolism. Vistusertib has been shown to be effective in the treatment of various cancers including solid tumours and platinum-resistant ovarian cancer. It has also been shown to have potential as a biomarker for autoimmune diseases because it inhibits autophagy.

Formula: C₂₅H₃₀N₆O₃

Purity: Min. 95%

Molecular weight: 462.54 g/mol

Ref: 3D-JQB29859

Osimertinib Impurity 1

CAS: 1009298-59-2

Formula: C₂₅H₃₀N₆O₃

Molecular weight: 462.55

Ref: ST-EA-CP-O17017